Top Tweets for #WMsm

14 days ago

#Myeloma Paper of the Day: Bortezomib in #Waldenström macroglobulinaemia pts who fail BTKi shows ORR of 88%; at median follow up of 39 mos, median treatment-free survival & overall survival were 18 (95% confidence interval 13-22) & 22 (17-45) mos: https://t.co/c9DqJRohU0. #wmsm

Myeloma_Doc's tweet photo. #Myeloma Paper of the Day: Bortezomib in #Waldenström macroglobulinaemia pts who fail BTKi shows ORR of 88%; at median follow up of 39 mos, median treatment-free survival & overall survival were 18 (95% confidence interval 13-22) & 22 (17-45) mos: https://t.co/c9DqJRohU0. #wmsm https://t.co/7PD9rj9tmI

0

11

1

5

1K

23 days ago

#Myeloma Paper of the Day: Measuring MYD88/CXCR4 mutation allele fraction in #Waldenström macroglobulinemia using a multiplex (7‐plex) ddPCR assay may have value both as a disease biomarker and as a prognostic indicator: https://t.co/AUqCwID5o9. #wmsm

$Myeloma_Doc's tweet photo. #Myeloma Paper of the Day: Measuring MYD88/CXCR4 mutation allele fraction in #Waldenström macroglobulinemia using a multiplex (7‐plex) ddPCR assay may have value both as a disease biomarker and as a prognostic indicator: https://t.co/AUqCwID5o9. #wmsm https://t.co/awLexrwNqE$

0

10

1

3

1K

2 months ago

#Myeloma Paper of the Day: Retrospective cohort study evaluating impact of osteolytic lesions on outcomes in pts w/ LPL/#Waldenstrom macroglobulinemia finds they do not affect diagnosis-to-treatment interval, response to 1st-line therapy, PFS or OS: https://t.co/BmSapuisiv. #wmsm

Myeloma_Doc's tweet photo. #Myeloma Paper of the Day: Retrospective cohort study evaluating impact of osteolytic lesions on outcomes in pts w/ LPL/#Waldenstrom macroglobulinemia finds they do not affect diagnosis-to-treatment interval, response to 1st-line therapy, PFS or OS: https://t.co/BmSapuisiv. #wmsm https://t.co/Ka6rl8Kexp

8

17

3

5

2K

2 months ago

#Myeloma Paper of the Day: 5-year follow-up of phase 1/2 BRUIN trial shows pirtobrutinib is active in relapsed or refractory #Waldenström w/ ORR of 82.5% (but only 1 CR (1.3%)), 81% if had prior BTKi; neutropenia & anemia were most common ≥G3 AEs: https://t.co/mgiUbL0ecG. #wmsm

$Myeloma_Doc's tweet photo. #Myeloma Paper of the Day: 5-year follow-up of phase 1/2 BRUIN trial shows pirtobrutinib is active in relapsed or refractory #Waldenström w/ ORR of 82.5% (but only 1 CR (1.3%)), 81% if had prior BTKi; neutropenia & anemia were most common ≥G3 AEs: https://t.co/mgiUbL0ecG. #wmsm https://t.co/roGACuQ3YU$

1

19

3

2

1K

Ajay Major, MD, MBA

@majorajay

3 months ago

Come join us on Saturday, May 2 for the @BloodCancerUtd 2026 Rocky Mountain Blood Cancer Conference! I'll be speaking about Waldenström macroglobulinemia and novel therapeutic approaches on the horizon. #lymsm #wmsm https://t.co/EMvyN5NbaC

majorajay's tweet photo. Come join us on Saturday, May 2 for the @BloodCancerUtd 2026 Rocky Mountain Blood Cancer Conference! I'll be speaking about Waldenström macroglobulinemia and novel therapeutic approaches on the horizon. #lymsm #wmsm
https://t.co/EMvyN5NbaC https://t.co/ov4YwDcuI2

0

9

2

0

294

Omer Raheem @OmerRaheemMD

3 months ago

#Myeloma Paper of the Day: CD3xCD20 bispecifics in transformed #Waldenström/lymphoplasmacytic lymphoma show estimated PFS @ 6 & 12 months of 59% & 51%, estimated OS rates of 79% & 57%; 15 pts (75%) experienced CRS (5% G3), 15% had ICANS (0% G3–4): https://t.co/rWakkLELgE. #wmsm

Myeloma_Doc's tweet photo. #Myeloma Paper of the Day: CD3xCD20 bispecifics in transformed #Waldenström/lymphoplasmacytic
lymphoma show estimated PFS @ 6 & 12 months of 59% & 51%, estimated OS rates of 79% & 57%; 15 pts (75%) experienced CRS (5% G3), 15% had ICANS (0% G3–4): https://t.co/rWakkLELgE. #wmsm https://t.co/6jQpuENy0X

1

15

7

3

1K

5 months ago

Great summary of the most recent ICSM recommendations 2026 published.⁦@sexmedjournals⁩ #SMR present today by .@DrHussain #WMSM 26.

OmerRaheemMD's tweet photo. Great summary of the most recent ICSM recommendations 2026 published.⁦@sexmedjournals⁩ #SMR present today by .@DrHussain #WMSM 26. https://t.co/8kK0jraxbi

0

13

4

1

965

Prof. Vaibhav Modgil | Uro Surgeon & Andrologist @VaibhavModgil

5 months ago

#WMSM Porto — good science, honest conversations, real collaboration. Proud to represent @ManchesterAndro @BAUSurology 🙏🏽 always good to see old old friends and make new ones!

VaibhavModgil's tweet photo. #WMSM Porto — good science, honest conversations, real collaboration. Proud to represent @ManchesterAndro @BAUSurology 🙏🏽 always good to see old
old friends and make new ones! https://t.co/yD83ByNkTz

1

32

4

0

1K

Angelo di Giovanni @AngelodiGiova

5 months ago

At #WMSM in beautiful Porto, presenting our St George’s experience using #Stimulan® antibiotic cast as an intracavernosal spacer in infected priapism before penile prosthesis insertion. #Andrology #PenileProsthesis #Priapism #Georgesurology

AngelodiGiova's tweet photo. At #WMSM in beautiful Porto, presenting our St George’s experience using #Stimulan® antibiotic cast as an intracavernosal spacer in infected priapism before penile prosthesis insertion.

#Andrology #PenileProsthesis #Priapism #Georgesurology https://t.co/IzFhvwGA6b

0

5

0

386

Dr Ward Sam

@dr_wardsam

5 months ago

14 days until I speak at the World Meeting on Sexual Medicine (#WMSM). Excited to discuss andrology, erectile dysfunction, and connect with colleagues worldwide. Sexual health deserves science, nuance, and open dialogue. #WardOfYourHealth #yoursexualhealthmatters

dr_wardsam's tweet photo. 14 days until I speak at the World Meeting on Sexual Medicine (#WMSM). Excited to discuss andrology, erectile dysfunction, and connect with colleagues worldwide. Sexual health deserves science, nuance, and open dialogue. #WardOfYourHealth #yoursexualhealthmatters https://t.co/ejczsQudr1

1

3

0

151

Celeste Manfredi @ManfrediCeleste

5 months ago

Proud to serve as Moderator at #WMSM 2026 in Porto. Sexual and reproductive health in testicular cancer survivors is a modern, often overlooked topic. Survivorship today means quality of life, masculinity, and fertility. These discussions matter!

ManfrediCeleste's tweet photo. Proud to serve as Moderator at #WMSM 2026 in Porto.
Sexual and reproductive health in testicular cancer survivors is a modern, often overlooked topic. Survivorship today means quality of life, masculinity, and fertility. These discussions matter! https://t.co/WzqW2EZGEv

1

3

0

144

Kareim M Khalafalla @Kareim_UroMD

7 months ago

Can’t Wait to attend the upcoming 27th #WMSM in #Porto See you there …

2

10

1

0

213

Ajay Major, MD, MBA

@majorajay

7 months ago

Pirto+ven R/R WM/LPL #ASH25 - 38 pts, 29 completed 6 cycles (total 24) - ORR 100%, VGPR/CR 56% - lower RR if CXCR4mut, TP53mut, prior cBTKi - 12-mo PFS 94% - MYD88wt pts (n = 2) w/ early PD Great all oral option for MYD88mut R/R WM. #lymsm #wmsm

majorajay's tweet photo. Pirto+ven R/R WM/LPL #ASH25
- 38 pts, 29 completed 6 cycles (total 24)
- ORR 100%, VGPR/CR 56%
- lower RR if CXCR4mut, TP53mut, prior cBTKi
- 12-mo PFS 94%
- MYD88wt pts (n = 2) w/ early PD
Great all oral option for MYD88mut R/R WM. #lymsm #wmsm https://t.co/xl1xBkTnsS

1

18

9

4

2K

Blood Cancer Journal @BloodCancerJnl

7 months ago

#wmsm

7 months ago

Long-term outcomes and treatment patterns in Waldenström macroglobulinemia patients who discontinue Bruton tyrosine kinase inhibitor (BTKi) therapy | Blood Cancer Journal https://t.co/QD5tiyyXX5

1

23

5

8

3K

0

3

1

1K

9 months ago

Hematology Tag Ontology (HTO) - @mtmdphd @subatomicdoc @audvin @symplur Symplur URLs broken, so I'll try to find a new place to post Intro & List and update from many suggestions over the years #ASH25 #ASHsm #leusm #lymsm #mmsm #mpnsm #wmsm cc @doctorpemm @TapKadia @drkomanduri

about 1 year ago

Hematology Tag Ontology (HTO) - @mtmdphd @subatomicdoc @audvin @symplur Intro: https://t.co/WnDSzsh0X2 List: https://t.co/Hs5CLMlkfg #ASHsm #18ICML #ICML2025 @icmlconf {work in progress}

mtmdphd's tweet photo. Hematology Tag Ontology (HTO) - @mtmdphd @subatomicdoc @audvin @symplur
Intro: https://t.co/WnDSzsh0X2
List: https://t.co/Hs5CLMlkfg
#ASHsm #18ICML #ICML2025 @icmlconf
{work in progress} https://t.co/cGbX0eQdNv

9

6

2

1K

0

3

0

645

9 months ago

Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE). @IreneGhobrial. A @SU2C / @DanaFarber research initiative to partner directly w/ Pts to accelerate discoveries in MM https://t.co/8ZUcXZKCYR #NCT03689595 #mmsm #wmsm #cancerdisparities

mtmdphd's tweet photo. Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE). @IreneGhobrial. A @SU2C / @DanaFarber research initiative to partner directly w/ Pts to accelerate discoveries in MM
https://t.co/8ZUcXZKCYR #NCT03689595 #mmsm #wmsm #cancerdisparities https://t.co/HXmlaZ0nHe

0

3

2

0

249

10 months ago

Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE). @IreneGhobrial. A @SU2C / @DanaFarber research initiative to partner directly w/ Pts to accelerate discoveries in MM https://t.co/8ZUcXZLaOp #NCT03689595 #mmsm #wmsm #cancerdisparities

0

5

1

0

359

10 months ago

Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE). @IreneGhobrial. A @SU2C / @DanaFarber research initiative to partner directly w/ Pts to accelerate discoveries in MM https://t.co/8ZUcXZKCYR #NCT03689595 #mmsm #wmsm #cancerdisparities

0

4

1

346